DePuy said it will use the technology to create patient-specific, bioresorbable implants for correcting orthopedic and craniomaxillofacial deformities and injuries.
“We are systematically investing in building a pipeline of 3D printed products. The TRS technology, which will be added to the DePuy Synthes Trauma Platform, is the latest example of how we are working toward developing next-generation technologies that transform healthcare delivery with individualized solutions for patients,”
DePuy Synthes began collaborating with TRS in 2014 through Johnson & Johnson Innovation, which seeks and invests in the best science and builds novel partnerships at all stages of development across the medical device, consumer healthcare and pharmaceutical sectors. Johnson & Johnson Innovation facilitated the collaboration between DePuy Synthes and TRS.
“The acquisition of the TRS technology by DePuy Synthes is testament to our ability to identify and work collaboratively with promising early-stage companies and entrepreneurs to accelerate bringing innovative new products to market,” said Robert G. Urban, PhD, Global Head, Johnson & Johnson Innovation. “We are excited at the potential this technology holds to help improve patient outcomes.”
Last month, DePuy Synthes released data from a new report on its Attune knee system, touting the economic benefits and value of procedures with the system to the new value-based healthcare environment.
In the report, researchers analyzed approaches for evaluating primary total knee arthroplasty procedures and assessed data from DePuy’s Attune knee evidence generation program, which includes data from independent studies, national joint registries and both investigator and company initiated studies.